Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KURA Kura Oncology, Inc

盘前交易 12-15 07:11:28 EST

10.22

-0.24

-2.29%

盘前10.35

+0.13+1.27%

04:39 EST

最高10.56	最低10.17	成交量147.94万
今开10.48	昨收10.46	日振幅3.73%
总市值8.89亿	流通市值6.54亿	总股本8,702万
成交额1,522万	换手率2.31%	流通股本6,399万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KURA","market":"US","secType":"STK","nameCN":"Kura Oncology, Inc","latestPrice":10.22,"timestamp":1765573200000,"preClose":10.46,"halted":0,"volume":1479446,"hourTrading":{"tag":"盘前","latestPrice":10.35,"preClose":10.22,"latestTime":"04:39 EST","volume":10,"amount":103.5,"timestamp":1765791545029},"delay":0,"floatShares":63985582,"shares":87017518,"eps":-2.480148,"marketStatus":"盘前交易","change":-0.24,"latestTime":"12-15 07:11:28 EST","open":10.48,"high":10.56,"low":10.17,"amount":15215047.265002001,"amplitude":0.037285,"askPrice":10.95,"askSize":100,"bidPrice":10.1,"bidSize":815,"shortable":3,"etf":0,"ttmEps":-2.480148,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765809000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1446699600000,"exchange":"NASDAQ","adjPreClose":10.22,"preHourTrading":{"tag":"盘前","latestPrice":10.35,"preClose":10.22,"latestTime":"04:39 EST","volume":10,"amount":103.5,"timestamp":1765791545029},"postHourTrading":{"tag":"盘后","latestPrice":10.5542,"preClose":10.22,"latestTime":"19:22 EST","volume":29788,"amount":304605.5579,"timestamp":1765585355778},"volumeRatio":0.9303212378064585,"impliedVol":0.7692,"impliedVolPercentile":0.4297},"requestUrl":"/m/hq/s/KURA","defaultTab":"news","newsList":[{"id":"1113707869","title":"Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1113707869","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113707869?lang=zh_cn&edition=full","pubTime":"2025-12-08 23:43","pubTimestamp":1765208596,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"1142603721","title":"美国首次商业销售Komzifti™触发Kura Oncology与Kyowa Kirin合作许可协议下的1.35亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1142603721","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142603721?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:03","pubTimestamp":1764680589,"startTime":"0","endTime":"0","summary":"美国首次商业销售Komzifti™触发Kura Oncology与Kyowa Kirin合作许可协议下的1.35亿美元里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2586921107","title":"Kura Oncology, Inc.盘中异动 股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586921107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586921107?lang=zh_cn&edition=full","pubTime":"2025-11-27 04:28","pubTimestamp":1764188885,"startTime":"0","endTime":"0","summary":"北京时间2025年11月27日04时28分，Kura Oncology, Inc.股票出现波动，股价快速上涨5.09%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.62%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。消息层面，截至04时28分，《LifeSci Capital维持Kura Oncology买入评级，维持目标价28美元》资讯为影响Kura Oncology, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127042805951c3885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127042805951c3885&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"1115337740","title":"Kura Oncology高管表示，Komzifti每日固定剂量一个月的美国上市价格为48,500美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115337740","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115337740?lang=zh_cn&edition=full","pubTime":"2025-11-14 01:55","pubTimestamp":1763056510,"startTime":"0","endTime":"0","summary":"Kura Oncology高管表示，Komzifti每日固定剂量一个月的美国上市价格为48,500美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"1160581625","title":"Kura Oncology高管表示已与FDA展开对话，为批准后改进标签做准备 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1160581625","media":"美股速递","labels":["executive","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160581625?lang=zh_cn&edition=full","pubTime":"2025-11-14 01:47","pubTimestamp":1763056030,"startTime":"0","endTime":"0","summary":"Kura Oncology高管表示已与FDA展开对话，为批准后改进标签做准备 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"1130437443","title":"Kura Oncology和Kyowa Kirin宣布Komzifti™（Ziftomenib）获得FDA批准，成为首个也是唯一每日一次的针对成人复发或难治性Npm1突变急性髓性白血病的靶向治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1130437443","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130437443?lang=zh_cn&edition=full","pubTime":"2025-11-13 23:52","pubTimestamp":1763049141,"startTime":"0","endTime":"0","summary":"Kura Oncology和Kyowa Kirin宣布Komzifti™（Ziftomenib）获得FDA的批准，成为首个也是唯一每日一次的针对成人复发或难治性Npm1突变急性髓性白血病的靶向治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"2581672797","title":"Kura Oncology, Inc.盘中异动 股价大跌6.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581672797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581672797?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:32","pubTimestamp":1762266728,"startTime":"0","endTime":"0","summary":"北京时间2025年11月04日22时32分，Kura Oncology, Inc.股票出现异动，股价快速下挫6.70%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.91%。其相关个股中，Terns Pharmaceuticals, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Artelo Biosciences, Inc.、Abpro Holdings, Inc、Biomx Inc.较为活跃，换手率分别为264.01%、82.32%、63.21%，振幅较大的相关个股有Abpro Holdings, Inc、Revelation Biosciences Inc C/Wts 10/01/2027 、Nuvation Bio Inc.，振幅分别为17.08%、13.56%、12.57%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104223209a6e0b5f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104223209a6e0b5f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"1127287316","title":"Kura Oncology Inc：我们相信截至2025年9月30日的现金、现金等价物和短期投资将足以覆盖到2027年的运营费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1127287316","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127287316?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:42","pubTimestamp":1762256576,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc：我们相信截至2025年9月30日的现金、现金等价物和短期投资将足以覆盖到2027年的运营费用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"gpt_icon":0},{"id":"1179163936","title":"Kura Oncology获3000万美元开发里程碑支付，推进Ziftomenib AML项目与Kyowa Kirin的合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1179163936","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179163936?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:03","pubTimestamp":1761303798,"startTime":"0","endTime":"0","summary":"Kura Oncology获3000万美元开发里程碑支付，推进Ziftomenib AML项目与Kyowa Kirin的合作","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2574973001","title":"Kura Oncology, Inc.盘中异动 早盘大幅上涨5.04%报9.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574973001","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574973001?lang=zh_cn&edition=full","pubTime":"2025-10-08 22:37","pubTimestamp":1759934279,"startTime":"0","endTime":"0","summary":"北京时间2025年10月08日22时37分，Kura Oncology, Inc.股票出现异动，股价大幅上涨5.04%。截至发稿，该股报9.91美元/股，成交量22.2946万股，换手率0.26%，振幅3.50%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008223759a6b0dc46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008223759a6b0dc46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KURA","BK4505"],"gpt_icon":0},{"id":"2572465301","title":"Kura Oncology, Inc.盘中异动 大幅上涨5.03%报9.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572465301","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572465301?lang=zh_cn&edition=full","pubTime":"2025-10-03 23:17","pubTimestamp":1759504636,"startTime":"0","endTime":"0","summary":"北京时间2025年10月03日23时17分，Kura Oncology, Inc.股票出现异动，股价大幅拉升5.03%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，Alto Neuroscience, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Alto Neuroscience, Inc.、Palisade Bio, Inc.、Ovid Therapeutics Inc.较为活跃，换手率分别为145.94%、111.32%、59.66%，振幅较大的相关个股有Alto Neuroscience, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Briacell Therapeutics Corp C/Wts ，振幅分别为55.10%、32.29%、32.25%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003231717971e8ca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003231717971e8ca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"1139652548","title":"Kura Oncology与Kyowa Kirin启动临床试验，评估在新诊断急性髓性白血病患者中对Npm1和Flt3突变的双重抑制效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1139652548","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139652548?lang=zh_cn&edition=full","pubTime":"2025-10-01 19:01","pubTimestamp":1759316509,"startTime":"0","endTime":"0","summary":"Kura Oncology与Kyowa Kirin宣布启动一项临床试验，该试验将评估在新诊断急性髓性白血病(AML)患者中对Npm1和Flt3突变进行双重抑制的治疗效果。\n这项合作研究旨在探索针对这两个关键突变靶点的联合治疗策略，为急性髓性白血病患者提供新的治疗选择。该临床试验将重点关注新确诊的AML患者群体，通过同时抑制Npm1和Flt3突变来评估治疗的安全性和有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"1100188247","title":"Kura Oncology与Kyowa Kirin宣布Ziftomenib治疗一线急性髓系白血病关键性3期Komet-017试验首位患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1100188247","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100188247?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:01","pubTimestamp":1759176083,"startTime":"0","endTime":"0","summary":"Kura Oncology与Kyowa Kirin宣布，针对一线急性髓系白血病（AML）的Ziftomenib关键性3期Komet-017试验已完成首位患者给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"2563007617","title":"Kura Oncology, Inc.盘中异动 下午盘大幅下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563007617","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563007617?lang=zh_cn&edition=full","pubTime":"2025-08-30 01:49","pubTimestamp":1756489762,"startTime":"0","endTime":"0","summary":"北京时间2025年08月30日01时49分，Kura Oncology, Inc.股票出现波动，股价快速跳水5.02%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Briacell Therapeutics Corp C/Wts 26/02/2026、Relmada Therapeutics, Inc.、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大，Tnf Pharmaceuticals, Inc.、Vivosim Labs, Inc.、Novabay Pharmaceuticals, Inc.较为活跃，换手率分别为43373.64%、430.20%、126.58%，振幅较大的相关个股有Vivosim Labs, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Relmada Therapeutics, Inc.，振幅分别为62.03%、56.67%、46.44%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250830014922a704a0d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250830014922a704a0d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"1132544169","title":"异动解读 | 库拉肿瘤股价盘中大跌5.70%，季度业绩远低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1132544169","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132544169?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:37","pubTimestamp":1754660249,"startTime":"0","endTime":"0","summary":"生物技术公司库拉肿瘤今日盘中大跌5.70%，主要原因是该公司公布的季度财报结果远低于分析师预期。根据公司最新发布的财报，截至6月30日的季度中，库拉肿瘤调整后每股亏损为0.75美元，远高于分析师平均预期的0.46美元亏损。尽管季度业绩不佳，分析师对库拉肿瘤的长期前景仍持积极态度。然而，考虑到公司连续几个季度的业绩表现不及预期，投资者可能需要重新评估其短期增长前景。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KURA"],"gpt_icon":0},{"id":"1151140223","title":"异动解读 | 库拉肿瘤公司股价盘中大跌5.70%，季度业绩远低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1151140223","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151140223?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:37","pubTimestamp":1754660244,"startTime":"0","endTime":"0","summary":"周五盘中，库拉肿瘤公司股价大幅下跌5.70%，主要原因是该公司公布的季度业绩远低于分析师预期。根据公司最新发布的财报显示，截至6月30日的季度，库拉肿瘤公司调整后每股亏损为0.75美元，远超分析师平均预期的0.46美元亏损。目前，分析师对库拉肿瘤公司股票的平均评级维持在\"买入\"，其中13个评级为\"强烈买入\"或\"买入\"，2个评级为\"持有\"，没有\"卖出\"或\"强烈卖出\"评级。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KURA"],"gpt_icon":0},{"id":"2557930413","title":"Kura Oncology, Inc.盘中异动 快速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557930413","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557930413?lang=zh_cn&edition=full","pubTime":"2025-08-07 03:28","pubTimestamp":1754508490,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日03时28分，Kura Oncology, Inc.股票出现波动，股价急速下挫5.03%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，Biomx Inc.、Rigel Pharmaceuticals, Inc.、Avidity Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Biomx Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为768.65%、710.21%、125.51%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 26/02/2026、Cingulate Inc C/Wts 10/12/2026 、Biomx Inc.，振幅分别为57.18%、51.96%、51.84%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807032810a4794172&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807032810a4794172&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2557336494","title":"Kura Oncology, Inc.盘中异动 下午盘股价大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557336494","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557336494?lang=zh_cn&edition=full","pubTime":"2025-08-05 02:51","pubTimestamp":1754333516,"startTime":"0","endTime":"0","summary":"北京时间2025年08月05日02时51分，Kura Oncology, Inc.股票出现异动，股价快速上涨5.15%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.45%。其相关个股中，Psyence Biomedical Ltd.、Bioxcel Therapeutics, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Psyence Biomedical Ltd.、Soligenix, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为6491.08%、1466.30%、969.43%，振幅较大的相关个股有凯信远达、Psyence Biomedical Ltd.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为92.95%、84.21%、80.73%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080502515694cf7057&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080502515694cf7057&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"2552240781","title":"Kura Oncology, Inc.盘中异动 股价大涨5.06%报6.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552240781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552240781?lang=zh_cn&edition=full","pubTime":"2025-07-17 00:29","pubTimestamp":1752683360,"startTime":"0","endTime":"0","summary":"北京时间2025年07月17日00时29分，Kura Oncology, Inc.股票出现波动，股价大幅拉升5.06%。截至发稿，该股报6.44美元/股，成交量100.195万股，换手率1.16%，振幅4.57%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.16%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071700292197a8a7d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071700292197a8a7d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"2549525089","title":"Kura Oncology, Inc.盘中异动 早盘快速拉升5.11%报5.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549525089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549525089?lang=zh_cn&edition=full","pubTime":"2025-07-08 22:48","pubTimestamp":1751986136,"startTime":"0","endTime":"0","summary":"北京时间2025年07月08日22时48分，Kura Oncology, Inc.股票出现异动，股价大幅上涨5.11%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.08%。其相关个股中，Seastar Medical Holding Corporation、Rallybio Corporation、Moleculin Biotech, Inc.涨幅较大，Zyversa Therapeutics, Inc.、Moleculin Biotech, Inc.、Rallybio Corporation较为活跃，换手率分别为942.05%、500.67%、270.98%，振幅较大的相关个股有Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Moleculin Biotech, Inc.、Rallybio Corporation，振幅分别为70.96%、69.44%、59.87%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708224856953af789&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708224856953af789&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KURA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kuraoncology.com","stockEarnings":[{"period":"1week","weight":-0.1448},{"period":"1month","weight":-0.0431},{"period":"3month","weight":0.2479},{"period":"6month","weight":0.587},{"period":"1year","weight":0.0547},{"period":"ytd","weight":0.1734}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kura Oncology, Inc.最初于2007年11月在特拉华州注册成立。他们是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的前景。他们的产品线由针对癌症信号通路的小分子候选产品组成，在这些信号通路中，有很强的科学和临床理由来改善结果，他们打算将其与分子或细胞诊断相结合，以确定最有可能对治疗做出反应的患者。他们正在对三种候选产品进行临床试验：齐夫托米尼、替比法尼和KO-2806。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.024387},{"month":2,"riseRate":0.5,"avgChangeRate":0.027496},{"month":3,"riseRate":0.6,"avgChangeRate":-0.029894},{"month":4,"riseRate":0.2,"avgChangeRate":-0.031764},{"month":5,"riseRate":0.5,"avgChangeRate":0.015121},{"month":6,"riseRate":0.5,"avgChangeRate":0.037607},{"month":7,"riseRate":0.5,"avgChangeRate":0.037366},{"month":8,"riseRate":0.5,"avgChangeRate":0.066679},{"month":9,"riseRate":0.5,"avgChangeRate":0.12103},{"month":10,"riseRate":0.3,"avgChangeRate":-0.077132},{"month":11,"riseRate":0.8,"avgChangeRate":0.052179},{"month":12,"riseRate":0.454545,"avgChangeRate":0.002397}],"exchange":"NASDAQ","name":"Kura Oncology, Inc","nameEN":"Kura Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kura Oncology, Inc(KURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kura Oncology, Inc,KURA,Kura Oncology, Inc股票,Kura Oncology, Inc股票老虎,Kura Oncology, Inc股票老虎国际,Kura Oncology, Inc行情,Kura Oncology, Inc股票行情,Kura Oncology, Inc股价,Kura Oncology, Inc股市,Kura Oncology, Inc股票价格,Kura Oncology, Inc股票交易,Kura Oncology, Inc股票购买,Kura Oncology, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kura Oncology, Inc(KURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}